http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer
-
Advaxis (ADXS) Plans ADXS-HER2 Poster Presentation at 2015 SABCS
-
Advaxis to Present Poster on ADXS-HER2 at SABCS 2015
-
Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
-
Advaxis to Receive $1.6 Million Through New Jersey Technology Business Tax (NOL) Program
-
Advaxis Presents New Data Featuring Its Lm Technology™ at the Society for Immunotherapy of Cancer 2015 Annual Meeting
-
Advaxis to Present at the Jefferies Autumn 2015 Global Healthcare Conference
-
Advaxis Provides Additional Information on Clinical Hold
-
Advaxis Launches MINE(TM) Collaboration
-
Advaxis’s Cancer Immunotherapies to be Featured in Three Poster Presentations at the 2015 SITC Annual Meeting
-
Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac
-
First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors
-
First Human Patient Treated in Phase 1b Study of Advaxis's ADXS-HER2 in HER2 Expressing Solid Tumors
-
Advaxis's Axalimogene Filolisbac (ADXS-HPV) Showed 38.5 Percent 12-Month Survival in Patients With Persistent/Recurrent Metastatic Cervical Cancer
-
FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac (ADXS-HPV) in HPV-Associated Head and Neck Cancer
-
FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac (ADXS-HPV) in HPV-Associated Head and Neck Cancer
-
Advaxis Accepts Medical Visionary Award From the Farrah Fawcett Foundation for Collaborative Research in HPV-Associated Anal Cancer
-
Advaxis Accepts Medical Visionary Award From the Farrah Fawcett Foundation for Collaborative Research in HPV-Associated Anal Cancer
-
Advaxis to Present at the 2015 Wells Fargo Securities Healthcare Conference
-
Advaxis to Present at the 2015 Wells Fargo Securities Healthcare Conference
-
Phase 2 Study of Advaxis's Axalimogene Filolisbac (ADXS-HPV) in Cervical Cancer to be Presented at 2015 AGOS Annual Meeting
-
Phase 2 Study of Advaxis's Axalimogene Filolisbac (ADXS-HPV) in Cervical Cancer to be Presented at 2015 AGOS Annual Meeting
-
Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management
-
Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management
-
Advaxis and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac (ADXS-HPV) in Combination With Durvalumab (MEDI4736) for the Treatment of HPV-Associated Cancers
-
Advaxis and MedImmune Commence Enrollment in Phase I/II Study of Axalimogene Filolisbac (ADXS-HPV) in Combination With Durvalumab (MEDI4736) for the Treatment of HPV-Associated Cancers
-
Advaxis Appoints Tom Ridge, America's First Secretary of Homeland Security and 43rd Governor of Pennsylvania, to Board of Directors
-
Advaxis Appoints Tom Ridge, America's First Secretary of Homeland Security and 43rd Governor of Pennsylvania, to Board of Directors
-
Advaxis's ADXS-PSA Awarded Research Grants From the Prostate Cancer Foundation and the Movember Foundation
-
Advaxis's ADXS-PSA Awarded Research Grants From the Prostate Cancer Foundation and the Movember Foundation
-
Advaxis's Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015
-
Advaxis's Scientific Founder to Present on ADXS-HER2 at World Congress on Breast Cancer 2015
-
Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2
-
Advaxis Expands Intellectual Property for Lm Technology(TM) Platform in HER2
-
Advaxis Appoints Dr. Shelonitda S. Rose as Vice President, Clinical Development
-
Advaxis's President and Chief Executive Officer Daniel J. O'Connor Receives 2015 Ernst & Young Entrepreneur Of The Year® in New Jersey
-
Advaxis Provides 2015 Half-Year Review and Outlook
-
Advaxis Selected for Inclusion in Russell Global and Russell 3000® Indexes
-
Advaxis to Hold Business Update Conference Call on June 25, 2015
-
Advaxis Submits Special Protocol Assessment Request to FDA for ADXS-HPV Phase 3 Clinical Trial in Cervical Cancer
-
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer
-
Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer
-
Advaxis Appoints World Renowned Oncologist and Research Scientist, Dr. Samir N. Khleif, to Its Board of Directors
-
Advaxis Provides a Clinical Development Update for Its Immunotherapy, ADXS-HPV, for the Treatment of Cervical Cancer
-
Advaxis to Present at Upcoming Investor Conferences
-
Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer
-
Advaxis's Scientific Founder, Dr. Yvonne Paterson, Named One of the PharmaVOICE 100 Most Inspiring People in Life Sciences
-
Advaxis and the University of Pennsylvania Restructure Their Exclusive License Agreement
-
Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial
-
Advaxis Announces Filing for USDA Product License
